ClinicalTrials.gg

COVID-19 clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 7,994 studies for COVID-19 across more than 10 countries. 468 are recruiting or about to start. 6,709 of them are mainly about COVID-19 (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Post-Acute COVID-19 Syndrome too: 8,396 studies, 618 open.

ClinicalTrials.gov finds 10,274 studies for COVID-19. How that becomes 7,993 here

This page counts the studies the registry files under COVID-19, and those it files under no condition that list COVID-19themselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 10,274Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −398Filed under a narrower condition, counted on its own pagePost-Acute COVID-19 Syndrome 397
  3. −167List COVID-19 as a condition, but the registry did not file them under itMost often written as “COVID-19 Pneumonia” (31), “COVID-19 Respiratory Infection” (25), and “COVID-19 Acute Respiratory Distress Syndrome” (13). The registry filed them under other conditions only, most often Respiratory Distress Syndrome (12) and Influenza, Human (12).
  4. −1,717Match it another way1,676 name it in the title, 21 in a keyword, and 20 by a synonym or other text the search reads.
  5. 7,992Counted here and found by its search417 of them list COVID-19 in their own words; the registry filed them under no condition.
  6. +1
    Counted here, but its search does not find them
  7. 7,993The count on this page

Status

Completed
4,437
Status unknown
1,801
Terminated
577
Withdrawn
386
Recruiting
356
Active, not recruiting
268

Phase

Phase 2
1,470
Phase 3
965
Phase 1
710
Phase 4
262
Early Phase 1
61

Where

United States
1,859
France
782
China
472
Spain
401
Turkey
398
Italy
392

Who develops what

Add COVID-19 to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 39 programs from 28 companies, 32 with this as their studies’ main aim; 6 with a live phase 3 study; 12 primary completions in the next 12 months. Compare BioNTech, Moderna and Pfizer here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
BNT162 VaccineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07936188 · GC Biopharma Corp. · Phase 2 · live · comparator · “COMIRNATY” · registered Oct 2026
  • NCT06742281 · CyanVac LLC · Phase 2 · comparator · “COMIRNATY®” · registered Dec 2024
  • NCT06672055 · Vaxart · Phase 2 · live · comparator · “COMIRNATY®” · registered Nov 2024
  • NCT05602961 · GreenLight Biosciences, Inc. · Phase 2 · background · “BNT162b2/COMIRNATY®” · registered Oct 2022
  • NCT05490108 · Shanghai Zerun Biotechnology Co.,Ltd · Phase 2 · comparator · “Comirnaty®” · registered Aug 2022
BioNTech SE87% of its industry studies1015 studies
mRNA COVID-19 VaccineRecent, repeated
Evidence
  • NCT07215520 · CastleVax Inc. · Phase 2 · live · comparator · “COVID-19 mRNA Vaccine” · registered Oct 2025
  • NCT05465902 · WestVac Biopharma Co., Ltd. · Phase 2 · comparator · “mRNA COVID-19 vaccine (Moderna)” · registered Jul 2022
  • NCT05442684 · CanSino Biologics Inc. · Phase 3 · comparator · “mRNA-based COVID-19 vaccine” · registered Jun 2022
  • NCT04878211 · Novartis · Phase 4 · background · “mRNA COVID-19 vaccine” · registered May 2021
Sanofi15% of its industry studiesEU: BioNTech SE (EMA 2020) + 1 other33 studies
ChAdOx1 nCoV-19Recent, repeatedPhase 4 trial recorded
Evidence
  • NCT05710783 · Laboratorio Avi-Mex, S.A. de C.V. · Phase 3 · comparator · “ChAdOx-1-S[recombinant]” · registered Dec 2022
  • NCT05603052 · EuBiologics Co.,Ltd · Phase 3 · comparator · “ChAdOx1 nCoV-19” · registered Nov 2022
  • NCT05572879 · EuBiologics Co.,Ltd · Phase 3 · comparator · “ChAdOx1 nCoV-19” · registered Oct 2022
  • NCT05426343 · Medigen Vaccine Biologics Corp. · Phase 3 · comparator · “AZD1222” · registered Jun 2022
  • NCT05198596 · Medigen Vaccine Biologics Corp. · Phase 3 · comparator · “AZD1222” · registered Jan 2022
AstraZeneca45% of its industry studies35 studies
Influenza VaccinesRecent, repeated
Evidence
  • NCT06864143 · Moderna, Inc. · Phase 2 · comparator · “Influenza Vaccine” · registered Mar 2025
  • NCT06694389 · Moderna, Inc. · Phase 3 · comparator · “Licensed Influenza Vaccine” · registered Nov 2024
  • NCT06279871 · Arcturus Therapeutics, Inc. · Phase 3 · background · “Influenza vaccine” · registered Feb 2024
  • NCT06178991 · BioNTech SE · Phase 3 · comparator · “Licensed influenza vaccine” · registered Dec 2023
  • NCT05091307 · Johnson & Johnson · Phase 3 · background · “Influenza Vaccine” · registered Oct 2021
—34 studies
COVID-19 VaccinesRecent, repeated
Evidence
  • NCT06864143 · Moderna, Inc. · Phase 2 · comparator · “COVID-19 Vaccine” · registered Mar 2025
  • NCT06694389 · Moderna, Inc. · Phase 3 · comparator · “SARS-CoV-2 Vaccine” · registered Nov 2024
  • NCT06178991 · BioNTech SE · Phase 3 · comparator · “COVID-19 Vaccine” · registered Dec 2023
  • NCT05480436 · Sinopharm · Phase 4 · comparator · “COVID-19 vaccine” · registered Jul 2022
—34 studies
Inactivated SARS-CoV-2 VaccineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT05465902 · WestVac Biopharma Co., Ltd. · Phase 2 · comparator · “COVID-19 Vaccine (Vero Cell), Inactivated” · registered Jul 2022
  • NCT05463354 · WestVac Biopharma Co., Ltd. · Phase 2 · comparator · “COVID-19 Vaccine (Vero Cell), Inactivated” · registered Jul 2022
  • NCT05463419 · Yisheng Biopharma (Singapore) Pte. Ltd. · Phase 3 · comparator · “Inactivated Covid-19 vaccine” · registered Jun 2022
  • NCT05323435 · Jiangsu Rec-Biotechnology Co., Ltd. · Phase 2 · comparator · “COVID-19 Vaccine (Vero Cell), Inactivated” · registered Apr 2022
Sinopharm47% of its industry studies34 studies
nirmatrelvir and ritonavir drug combinationRecent, repeated
Evidence
  • NCT07157007 · Traws Pharma, Inc. · Phase 2 · comparator · “Paxlovid” · registered Sep 2025
  • NCT05341609 · Vigonvita Life Sciences · Phase 3 · comparator · “Paxlovid” · registered Apr 2022
Pfizer100% of its industry studiesEU: Pfizer (EMA 2022)22 studies

12 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
BNT162 VaccinePhase 4 trial recorded☆ Track1 live phase-3 study: NCT07798648BioNTech SE
secutrelvir☆ Track2 live phase-3 studies: NCT07743580, NCT07746544Shionogi
ibuzatrelvir☆ Track2 live phase-3 studies: NCT06679140, NCT07013474Pfizer
remdesivirApproved: US 2020 · EU 2020☆ Track1 live phase-3 study: NCT07013474Pfizer
molnupiravir☆ Track1 live phase-3 study: NCT06667700Merck & Co., Inc

The 5 in phase 3 with the nearest primary completion, of 39 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (12)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 26 Nov 2026 est.NVX-CoV2373 adjuvated lipid nanoparticle · Sanofi · Phase 4 main aimNCT07861542 Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 — primary endpoint: Geometric Mean Fold Rise (GMFR) in pseudovirus neutralizing antibody titers (ID50) against the Omicron subvariant included in the vaccine formulation from pre-vaccination to 28 days post-vaccination. · 669 enrolled
  • 11 Dec 2026 est.MRNA-1283, 2019-nCoV Vaccine mRNA-1273 · Moderna, Inc. · Phase 4 main aimNCT07863635 A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations — primary endpoint: Geometric Mean Titer (GMT) of Neutralizing Antibody (nAb) Against Vaccine-matched Variant Formulation · 600 enrolled
  • 31 Dec 2026 est.2019-nCoV Vaccine mRNA-1273 · Moderna, Inc. · Phase 4 main aimNCT06585241 A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations — primary endpoint: mRNA-1273.167, mRNA-1273.712, mRNA-1273.251, and mRNA-1273.261: Geometric Mean Value of Neutralizing Antibody Against COVID-19 Variants · 1,144 enrolled

9 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in COVID-19 studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 open · JAK inhibitors 4 open · Corticosteroids 2 open · NSAIDs 2 open · SGLT2 inhibitors 2 open

Coming up

148studies finish main data collection within a year11 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger. 91 (26%) take children under 18. 12 (3%) are for women only and 1 (<1%) for men only; 135 (38%) take healthy volunteers.

Recruiting studies that take each age, of 356
AgeWomenMen
1067 (19%)66 (19%)
18320 (90%)310 (87%)
30323 (91%)313 (88%)
40324 (91%)314 (88%)
50325 (91%)315 (88%)
65312 (88%)306 (86%)
75283 (79%)277 (78%)
85251 (71%)245 (69%)

Across all 7,994 studies, recruiting or not: 22% stop at 75 or younger and 16% at 65; 17% take children; 2% are for women only and 1% for men only; 34% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long COVID-19 studies take

Of 583 phase 2 interventional studies under COVID-19, half reached primary completion within 9 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 17 mo3–15 · 384 studies6 mo2–12 · 233 studies11 mo5–19 · 151 studies
Phase 1/211 mo4–20 · 187 studies10 mo5–19 · 80 studies11 mo3–21 · 107 studies
Phase 29 mo5–16 · 583 studies8 mo5–13 · 224 studies11 mo5–18 · 359 studies
Phase 2/311 mo5–19 · 168 studies10 mo5–18 · 73 studies11 mo5–22 · 95 studies
Phase 39 mo4–17 · 453 studies8 mo4–16 · 168 studies10 mo5–19 · 285 studies
Phase 48 mo4–18 · 189 studies5 mo3–12 · 44 studies9 mo5–19 · 145 studies
Interventional, no phase9 mo3–19 · 1,475 studies5 mo2–11 · 138 studies9 mo3–20 · 1,337 studies
Observational13 mo5–29 · 1,775 studies10 mo3–19 · 134 studies14 mo5–30 · 1,641 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 7,994. Browse all 7,994 → or search them.